[
  {
    "ts": null,
    "headline": "Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting Phase 3 data on first in class antibody therapies for cat and birch allergies at the AAAAI 2026 meeting. The company is also sharing new long term real world and clinical data for Dupixent across dermatological, respiratory, and gastrointestinal conditions, including in children. These updates highlight a potential new approach to allergen blocking along with broader evidence for Dupixent across multiple indications. Regeneron...",
    "url": "https://finnhub.io/api/news?id=c7a04a57325fca9f249ac3e6b3c311fd48782cc30f1dd5827165de220b8a3f11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771006360,
      "headline": "Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects",
      "id": 139088141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting Phase 3 data on first in class antibody therapies for cat and birch allergies at the AAAAI 2026 meeting. The company is also sharing new long term real world and clinical data for Dupixent across dermatological, respiratory, and gastrointestinal conditions, including in children. These updates highlight a potential new approach to allergen blocking along with broader evidence for Dupixent across multiple indications. Regeneron...",
      "url": "https://finnhub.io/api/news?id=c7a04a57325fca9f249ac3e6b3c311fd48782cc30f1dd5827165de220b8a3f11"
    }
  },
  {
    "ts": null,
    "headline": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y",
    "summary": "RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.",
    "url": "https://finnhub.io/api/news?id=d9e168fc4859ae5dfa41f2bdfec727c2247a5034436a9442b837c43c0ad57524",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770996180,
      "headline": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y",
      "id": 139086698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.",
      "url": "https://finnhub.io/api/news?id=d9e168fc4859ae5dfa41f2bdfec727c2247a5034436a9442b837c43c0ad57524"
    }
  },
  {
    "ts": null,
    "headline": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
    "url": "https://finnhub.io/api/news?id=52cec603be9bdb03eeddeda35462e9868e0fd4411b17ffdaa36af8fdcda6552d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994656,
      "headline": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
      "id": 139085192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
      "url": "https://finnhub.io/api/news?id=52cec603be9bdb03eeddeda35462e9868e0fd4411b17ffdaa36af8fdcda6552d"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
    "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
    "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993949,
      "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
      "id": 139095930,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Crispr-Therapeutics.jpeg?width=2048&height=1536",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
      "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors",
    "summary": "Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.",
    "url": "https://finnhub.io/api/news?id=490ace136593343a474f253b3be1e2c43b7e12e36f2df67a4e70044375919303",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770974604,
      "headline": "Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors",
      "id": 139082625,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?width=2048&height=1536",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.",
      "url": "https://finnhub.io/api/news?id=490ace136593343a474f253b3be1e2c43b7e12e36f2df67a4e70044375919303"
    }
  },
  {
    "ts": null,
    "headline": "Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells",
    "summary": "Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells",
    "url": "https://finnhub.io/api/news?id=383667de15b03e5eb637ab68c58169b3f47a495f1122b8a0b4ad9478c416eae8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770961500,
      "headline": "Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells",
      "id": 139079385,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=383667de15b03e5eb637ab68c58169b3f47a495f1122b8a0b4ad9478c416eae8"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock Worth Your Attention and 2 Facing Challenges",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.",
    "url": "https://finnhub.io/api/news?id=4344026237cb46c3b3c47213c9a887110470abec7aa45a9ca1a4da72cc4b5590",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770957569,
      "headline": "1 Healthcare Stock Worth Your Attention and 2 Facing Challenges",
      "id": 139089832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.",
      "url": "https://finnhub.io/api/news?id=4344026237cb46c3b3c47213c9a887110470abec7aa45a9ca1a4da72cc4b5590"
    }
  }
]